How will Malaysia study clinical data on AstraZeneca vaccine incidents abroad?

Question

Accepted Answer

Malaysia to Study Overseas Clinical Data on AstraZeneca Vaccine Incidents

Malaysia will proceed with the acquisition of AstraZeneca Covid-19 vaccines, with the Ministry of Health committed to studying clinical data from incidents that have occurred abroad. This approach aims to enable local experts to draw informed conclusions regarding the vaccine's use within the country. The National Pharmaceutical Regulatory Division (NPRA) has already conducted thorough safety and quality assessments, leading to the conditional registration of the AstraZeneca vaccine by the Drug Control Authority (DCA) on March 2.
Ministry to Review Global Clinical Data

The Ministry of Health intends to meticulously examine the clinical data pertaining to adverse events reported internationally concerning the AstraZeneca vaccine. This review is a crucial step to ensure that Malaysian experts have access to the most comprehensive information available, allowing them to make well-founded decisions about the vaccine's ongoing deployment. This proactive stance demonstrates a commitment to evidence-based public health policy.
No Evidence of Direct Link to Blood Clots

Official statements indicate that AstraZeneca has communicated potential side effects of its vaccine to Malaysia. However, as of the reporting, there is no data substantiating a direct causal link between the vaccine and the blood clot incidents that have prompted some countries to pause their vaccination programmes. This lack of direct evidence supports Malaysia's decision to continue with its procurement plans.
NPRA Conducts Thorough Vaccine Assessments

The National Pharmaceutical Regulatory Division (NPRA) plays a pivotal role in ensuring the safety and efficacy of all Covid-19 vaccines used in Malaysia. The division undertakes rigorous studies for each vaccine candidate, including comprehensive evaluations of quality and safety profiles. This established process underpins the trust placed in the NPRA's recommendations by the Malaysian authorities.
Conditional Registration Granted by DCA

The Drug Control Authority (DCA) granted conditional registration for the AstraZeneca Covid-19 vaccine on March 2. This approval signifies that, following thorough review by regulatory bodies, the vaccine meets the necessary standards for use during the ongoing pandemic, albeit with ongoing monitoring and data collection as standard practice for newly approved medical interventions.

Reading history

Hide →

This history is cleared when the page is closed.

How will Malaysia study clinical data on AstraZeneca vaccine incidents abroad?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends